share_log

Keybanc Initiates Coverage On AbCellera Biologics With Overweight Rating, Announces Price Target of $6

Benzinga ·  Dec 5, 2023 06:03

Keybanc analyst Scott Schoenhaus initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment